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Introduction 
Age-related macular degeneration (AMD) is the leading cause of blindness in 
the United Kingdom, with AMD responsible for more people being registered as 
‘sight impaired’ or ‘severely sight impaired’ than all other ocular conditions 
combined.1 The prevalence of AMD is expected to increase globally between 2005 
and 2050 due to a predicted 3 fold increase in the number of people aged over 60 
years.2 Age-related macular degeneration manifests either as choroidal 
neovascularisation (wet AMD) or geographic atrophy (dry AMD), whilst early AMD, 
also known as age-related maculopathy (ARM), is characterised by soft drusen and 
focal pigmentary changes only.3 Currently treatment is only available for the wet 
(neovascular) type of AMD, usually in the form of anti-angiogenic pharmacotherapy.4 
Although no treatment currently exists for dry AMD and early AMD there is some 
evidence to suggest that nutritional supplements may slow the progression of the 
disease.5 The ability to accurately diagnose the onset of AMD and to monitor 
disease progression is vital in the early identification of patients suitable for therapy, 
and in evaluating the outcomes of the treatment.  
Historically, the diagnosis and grading of AMD has largely been based on 
visual acuity and stereoscopic fundus photographs.3 However, in recent years 
detailed analysis of retinal microscructure has become possible in the form of optical 
coherence tomography (OCT), and offers an extra dimension to the evaluation of 
age-related macular disease.6 OCT is a technique which utilises the optical 
equivalent of the echo time delay in ultrasound to construct a cross-sectional image 
of the retina in vivo, analogous to a histological section.  
Frequency domain OCT (FD-OCT) has traditionally used light sources with a 
bandwidth based around 800nm.6 The limitation of this band of wavelengths is partly 
that ocular opacities can degrade the quality of the collected image (which is 
especially important in the assessment of elderly individuals), but also that the high 
level of scatter by retinal tissue and increased absorption by the retinal pigment 
epithelium (RPE) results in limited visualisation of sub RPE layers.7-9 An alternative 
light source, with a bandwidth based around 1060nm, has been shown to allow 
deeper penetration into the choroidal tissue and better signal-to-noise ratio in the 
presence of media opacities.7, 9-11  
Although the longer wavelength 1060nm OCT is the first system which allows 
a reliable assessment of in vivo choroidal thickness in all patients, it has only been 
used to date to assess outer retinal features and choroidal structure in patients with 
the neovascular form of AMD,12 where the structural changes to the choroid/Bruch’s 
membrane/RPE complex are already marked. There is substantial evidence to 
suggest that the dynamics of the choroidal circulation are affected earlier in the 
disease process (see Harris et al. 1999 for review 13), and histological studies have 
found evidence of a difference in choroidal structure in eyes with early and advanced 
AMD compared to age-matched control eyes, such as reductions in choriocapillary 
density and choroid thickness.14-16 However, histological evidence regarding 
choroidal thickness in AMD is mixed, with some evidence to suggest a reduction, 
particularly in the advanced stages of the disease,15-16 whilst another study found no 
significant change in choroidal thickness, even in advanced AMD.14  
The aim of this study was to use the 1060nm enhanced choroidal penetration 
OCT to investigate retinal and choroidal thickness as a function of eccentricity in 
patients with early AMD (drusen or pigmentary changes only). This will help 
determine the potential clinical value of the 1060nm OCT in assessing early macular 
disease, and provide an insight into the earliest structural changes occurring in AMD. 
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Methods 
Participants 
Control participants (n=16) and those with early AMD (n=16) were recruited 
for this study from staff, students and volunteers attending the Eye Clinic at the 
School of Optometry and Vision Sciences and the Eye Unit at the University Hospital 
of Wales. All participants had a corrected visual acuity (VA) of 0.3 logMAR (~20/40) 
or better assessed using an Early Treatment of Diabetic Retinopathy Study (ETDRS) 
sight chart and a refractive error of less than ±6D. Participants were excluded if they 
had secondary retinal disease, significant cataract (Lens Opacities Classification 
System III grade 4 or above for any criteria 17) or narrow irido-corneal angles (Grade 
1 or less assessed by Van Herick). Each participant was given a full explanation of 
the procedures involved and their written informed consent was obtained before 
participation in the study. 
Participants were categorised into either a “Control” or “early AMD” group 
dependent on the assessment of 37° digital fundus images (CR-DGi Non mydriatic 
retinal camera, Canon, Inc. Lake Success, USA) and 20° 1060µm OCT images. 
Images were assessed for AMD related features located within a 6000µm diameter 
centred on the fovea. Definitions were based on the International 3 and the Age 
Related Eye Disease Study (AREDS) 18 AMD classification systems. Control 
participants exhibited no features associated with AMD, with any drusen present 
being less than 125µm in diameter (hard drusen). Early AMD was defined as the 
presence of soft drusen (>125µm diameter), pigment changes or drusenoid pigment 
epithelial detachment (PED) in the absence of any feature of advanced AMD (wet or 
dry) as defined by the AREDS grading system.18 Classification was carried out by 
the author AW, and confirmed independently by AB and TM. One drop of 
Tropicamide 1.0% was instilled into the both eyes of each participant, ensuring pupil 
dilation of at least 7mm prior to obtaining fundus photographs and OCT images. 
Images were obtained from both eyes of all individuals, to determine their AMD 
status. One eye was selected for analysis from each participant; this was the eye 
with a diagnosis of early AMD or, in the case of bilateral early AMD or controls, the 
eye with the better VA, with the left eye used as default. 
Three-dimensional OCT-imaging at 1060nm was performed with less than 
2.5mW at the cornea, below the maximum power limit for a 10s exposure.19-20 OCT 
volumes were acquired across a 20°×20° (5.76 x 5.76mm) field consisting of 
512×512 A-scans obtained at a rate of 47,000 A-scans/second (~8µm axial 
resolution). OCT volumes were centred on the fovea, aligned by participant fixation. 
Axial length (cornea-RPE) measurements were acquired using optical biometry (IOL 
Master Zeiss, Jena, Germany), for each eye five measurements were averaged.  
Image processing and analysis was undertaken using ImageJ software 
(ImageJ. Bethesda, Maryland, USA). Raw OCT images were digitally enhanced to 
improve the visibility of the retina and choroidal boundaries. Post-processing 
procedures were carried out subjectively and included: adjustments to brightness 
and contrast, b-scan registration, despeckling/noise removal and application of 
Gaussian or Convolving blur.  Measurements were made using the calliper function 
in the axial plane of the images. The thickness represented by each pixel was 
calculated assuming a refractive index of 1.4.  
Retinal thickness was measured from the most anterior hyper-reflective line, 
which corresponds to the inner limiting membrane (ILM), to the centre of the most 
posterior hyper-reflective line which corresponds to the RPE. Choroidal thickness 
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was measured from the RPE, to the choroid-sclera boundary. Thickness 
measurements were obtained for both retina and the choroid at the fovea, and then 
at 0.5mm intervals out to 2mm nasally (N), temporally (T), superiorly (S) and 
inferiorly (I) (see Figure 1). This produced thickness measurements at 17 individual 
retinal locations for each eye. At each location the distribution of thickness 
measurements was checked for normality and an independent t-test was conducted 
between the control and early AMD groups. 
Additionally the fundus and OCT images were assessed subjectively, 
specifically the participants regarded at the highest risk of  progression to advanced 
AMD (i.e. those with drusenoid PED, 21 confluent drusen or a fellow eye with 
advanced AMD 18) were compared to those at lowest risk (i.e. those with normal 
fellow eyes and none of the high-risk features listed above).  
 
Results 
The study involved 32 participants consisting of a control (n=16) and early 
AMD (n=16) group. The control group (n=16) had a mean age of 67.6±5.4 years, and 
a mean axial length of 23.7±0.8 mm.  The early AMD group (n=16) had a mean age 
of 71.6±8.5 years, and a mean axial length of 23.2±0.7 mm. The mean age (P=0.12, 
independent t-test) and axial length (P=0.09, independent t-test) of the two groups 
were not significantly different. The clinical features of the participants with early 
AMD are shown in Table 1. 
The mean retinal thickness for participants in the control and early AMD 
groups was plotted for each retinal location and is shown in Figure 2 for the 
horizontal meridian and Figure 3 for the vertical meridian. The mean retinal thickness 
was found to be smallest at the fovea (F) for both groups, increasing with eccentricity 
in both vertical and horizontal meridians to reach a maximum at 1mm, before 
declining with further increase in eccentricity. Central retinal thickness, measured at 
the fovea (F), was 202±18µm for the control group, and 179±27µm for the early AMD 
group, this difference was significant (P=0.008). Table 2 shows mean retinal 
thickness at each retinal location and the P-value for the difference between the 
groups. The early AMD group was found to have significantly thinner retinal 
thickness values at the fovea and eccentricities out to 1 mm, extending to 1.5 mm 
temporally.  
Mean choroidal thickness was plotted for each retinal location measured 
along horizontal and vertical meridians (Figures 4 and 5). In the horizontal meridian, 
choroidal thickness was found to be greatest at the fovea (F), decreasing to a 
minimum nasally, and showing a more modest reduction in thickness temporally. 
There was less variation in choroidal thickness in the vertical meridian. Central 
choroidal thickness, measured at the fovea (F), was 213±63 µm for the control 
group, and 231±70 µm for the early AMD group, this difference was not significant 
(P>0.05, independent t-test).  Table 3 shows mean choroidal thickness at each 
retinal location and the P-value for the difference between each group, the difference 
between groups was not significant at any location for choroidal thickness.  
OCT and macular photographs of those at most and least risk of progression 
to advanced AMD were compared subjectively to identify qualitative differences. 
Participant 1 (Figure 6), has a low risk of progression to advanced AMD22 , whereas 
participant 14 is at high risk of progression.21 A common feature identified on the 
OCT images of both participants was a localised thinning of the photoreceptor layer 
overlying drusen or pigment epithelial detachments, this is exemplified in Figure 6, 
although underlying choroidal thickness appears unaffected. 
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Discussion  
This study used enhanced choroidal penetration (1060nm) OCT to assess the 
thickness of the choroid in patients with early AMD. It was found that retinal 
thickness differed significantly at the fovea, and at a number of extrafoveal points, 
between individuals with early AMD and age-matched controls. However, there were 
no significant differences in choroidal thickness at any eccentricity assessed.  
The one previous study which used a 1060nm OCT system to evaluate the 
choroid in age-related macular disease recruited participants with the late, 
neovascular form of AMD (n=12).12 Yasuno et al. compared images obtained using 
long wavelength OCT to the standard 830nm FD-OCT in visualising the morphology 
of structures beneath the RPE, such as choroidal neovascular membranes. They 
found a general improvement in the image contrast of sub-RPE structures in most 
eyes and, in 3 eyes, were able to see hyper-reflective structures beneath the 
choroidal neovascular membranes, not accessible using the 830nm OCT. However, 
the study did not evaluate disease-related changes in the thickness of the choroid. 
This study provides in vivo evidence that choroidal thickness may not be 
affected by early AMD. Histological studies have been carried out to investigate the 
cross-sectional area and thickness of the choriocapillaris of donor eyes from 
individuals with early and advanced AMD. 14-16 Our data are in agreement with a 
study reporting a significant decrease in choriocapillary density in 25 eyes with 
features of AMD, but finding no significant decrease in the thickness of the choroid 
compared to age-matched controls.14 Our data are also supported by a recent study 
by Chung et al. (2011) evaluating choroidal thickness in early AMD using the 870nm 
OCT with an enhanced depth imaging technique. They also found a small, but 
statistically non-significant reduction in subfoveal choroidal thickness in the 
individuals with early AMD, compared to age-matched controls.23  
However, there is evidence to suggest that choroidal thinning may occur in 
end-stage AMD.15-16, 23 McLeod et al. examined the post-mortem choroid in 3 aged 
control eyes, 5 with geographic atrophy, and 3 with neovascular AMD and reported a 
linear relationship between the loss of RPE and choriocapillaris in geographic 
atrophy, and a 50% reduction in choroidal vascular cross-sectional area in eyes with 
wet AMD, even in the absence of RPE atrophy.15 Sarks carried out a histological 
study on 378 eyes from patients aged 43-97 years, who had either normal fundi or 
some degree of AMD.16 They reported thinning of the choroid, resulting in a ‘tigroid’ 
fundus appearance. Thinning was associated with increasing age both in aged 
patients classified as clinically normal and in those with all stages of AMD, but it was 
particularly prevalent in those with advanced AMD. A significant reduction in in vivo 
subfoveal choroidal thickness has also been reported in individuals with exudative 
AMD, in a study which used 870nm enhanced depth imaging OCT.23 
Although there is strong evidence for the occurrence of age-related thinning of 
the choroid,14, 16, 24 and for changes in choroidal perfusion in early AMD,13, 25-26 
evidence for thinning of the choroid specific to early AMD is not apparent in the 
literature. Our findings would suggest that any changes in the perfusion and blood 
flow dynamics of the choriocapillaris associated with early AMD are independent of 
choroidal thickness.  
Multiple studies have assessed choroidal thickness in healthy individuals 
using the OCT,23-24, 27-30 however, only a few have used a 1060nm system.27-28 A 
recent study using 1060nm OCT to investigate the correlation between axial length 
and choroidal thickness in 34 healthy subjects (64 eyes) aged 19-80 years, found a 
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mean central choroidal thickness of 315m (SD 106m), with the choroid thinnest in 
the nasal parafovea.27 Other studies have also found choroidal thickness to be 
greatest at the fovea, with a greater reduction in thickness with eccentricity reported 
nasally than temporally,23-24, 28, 30 a pattern reflected in our findings from both controls 
and individuals with early AMD. The mean subfoveal choroidal thickness reported 
has varied between studies from 225m (SD 53m),23 to 354nm (SD 111m).28 The 
control group employed in our study was found to have a slightly lower mean 
subfoveal choroidal thickness of 213m (SD 63m), which may reflect the greater 
mean age of the participants than in most previous studies.  
A manual technique was used to identify the boundaries and measure the 
retinal and choroidal thickness in this study. Although more time-consuming than 
automated systems, there is evidence to suggest that manual measurement is more 
accurate, especially in the presence of disruption caused by diseases such as 
AMD.31-33 Using this strategy, the mean retinal thickness was found to be lower in 
individuals with early AMD than in controls at all eccentricities; this reached statistical 
significance at the fovea and at extra foveal locations up to 1 mm eccentricity in all 
meridians .  
Multiple comparisons were carried out in this study (17 retinal locations were 
evaluated). If these were unrelated variables then one might expect the null 
hypothesis to be wrongly rejected in 1 comparison out of 20 through chance alone 
(i.e. multiple testing increases the risk of a type I error). However, in this study, the 
retinal thickness measurements at different retinal locations were highly correlated, 
(mean r=0.72 across all retinal locations, Pearson’s correlation coefficient). When 
variables tested are correlated, the risk of a type I error decreases as the probability 
of the null hypothesis being rejected due to chance is not multiplicative of the 
probability of each individual comparison being found significant by chance alone.34 
However, even if a correction method such as that described by Sankoh et al. is 
used,35 which factors in the correlation between variables, retinal thickness remains 
significantly reduced in individuals with early AMD at the fovea (P=0.019), 0.5mm 
inferiorly (P= 0.039) and 0.5mm temporally (P=0.023).  
A number of studies have used OCT to evaluate retinal thickness in eyes with 
advanced dry or wet AMD,36-40 but there is less evidence regarding retinal thickness 
assessed using OCT in early AMD.41-43 One study using FD-OCT on 17 eyes with 
early AMD and 17 healthy control eyes reported that photoreceptor layer thickness is 
reduced over drusen in eyes with early AMD, but that there is no evidence of a 
generalised reduction in thickness across the macular region.43 Similarly, Kaluzny et 
al.41 used FD-OCT to identify focal changes in retinal thickness in 24 eyes with soft 
drusen, localised to the position of the drusen. They reported evidence of 
photoreceptor atrophy anterior to the drusen, but not diffusely present across the 
macula. Malamos et al.42 used FD-OCT to evaluate macular changes in 12 
individuals with early AMD, as well as 37 with choroidal neovascularisation. They 
also found that discrete thinning of the retina above underlying drusen was the only 
abnormality in retinal thickness in patients with early macular disease, and that this 
was not sufficient to influence mean thicknesses of annuli centred on the fovea. This 
localised reduction in retinal thickness has been ascribed to the outer retina, with 
Schuman et al.43 finding inner retinal thickness to be almost unchanged over drusen. 
It is possible that the finding of a reduced retinal thickness in individuals with 
early AMD in our study reflects the photoreceptor degeneration reported to occur 
overlying drusen.41-43 Although drusen areas were not specifically targeted for our 
measurements, subjective assessment of the images showed localised thinning of 
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the photoreceptor layer overlying drusen and PED (Figure 6). Histological findings 
from human donor eyes have suggested that a loss of photoreceptors (with a 
predilection for rods over cones) occurs in non-exudative AMD, which may explain 
such a reduction in retinal thickness.44 The difference in retinal thickness between 
individuals with early AMD and age-matched controls in this study extended out up 
to 1.5 mm (5.2) eccentricity. Curcio et al. 44 also reported that the location of 
greatest cell loss in age-related macular disease occurs within the 
parafovea/perifoveal region, from 1.5-10 from fixation. Further investigation of the 
individual intraretinal layer thicknesses and their relationship to clinical features in 
early AMD patients may indicate the cause or location of the retinal thickness loss 
identified.  
Legaretta et al.45 and Kakinoki et al.46 reported foveal retinal thickness in 
healthy subjects of 258.2µm (SD 23.5µm) and 257.6µm (SD 19.6µm) respectively; 
thicker than the 202 m (SD 18m) found in this study. Both of these studies used 
the Cirrus OCT, 45-46 which utilised the same retinal boundaries as this study but 
measured the foveal thickness as an average over 500 µm centred on the fovea 
rather than at the foveola as in this study. The values found in this study are 
comparable to myopic foveal thickness measurements using a similar methodology 
to our own,29 and to minimum foveal thickness in normal eyes found using a stratus 
OCT.45-47 
Our overall approach to the analysis was conservative because we adopted 
an independent samples rather than a paired approach, despite having matched our 
groups for age and axial length. Based on the standard deviation of the foveal 
thickness measurements and the sample size, the smallest difference between 
groups detectable in this study was 24.8 and 64.7 µm for retinal and choroidal 
thickness respectively (with a power of 80% and a significance level of 0.05).48 
Intraobserver reliability has previously been assessed for retinal and choroidal 
thickness measurements by observer AW using the manual measurement technique 
employed in this study. Using the Bland and Altman technique,49 the intraobserver 
coefficient of repeatability for measurement of foveal retinal thickness on two 
separate occasions was 18.9 µm for individuals with early AMD (n=17) and 15.7 µm 
for healthy control participants (n=24). For choroidal thickness measurements, an 
intraobserver coefficient of repeatability of 58.7 and 35.6 µm was obtained for early 
AMD and control participants respectively. This study was therefore powered to 
detect any difference which was greater than the measurement error of the 
technique.  
Whilst a modest, but significant, reduction in retinal thickness in early AMD 
was shown, no significant change in choroidal thickness was found during this study. 
These findings suggest that measurement of choroidal thickness using OCT is not 
diagnostic for early age-related macular disease.  
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Figure Captions 
 
FIGURE 1: Optical coherence tomography (OCT) layer boundaries and 
measurement locations used in this study. (Left) A cross sectional 1060nm OCT b-
scan, the superior row of arrows indicating the location of the inner limiting 
membrane (ILM), middle row the retinal pigmented epithelium (RPE) and the inferior 
row choroid-sclera boundary. These features were used to delineate the boundaries 
of the retina and choroid for thickness measurements. (Right) A fundus photograph 
with retinal locations overlaid (solid dots) at which each retinal and choroid thickness 
measurement was obtained. Retinal direction is indicated by S (Superior), I (Inferior), 
N (Nasal), and T (Temporal) as labelled.  
 
FIGURE 2: Retinal thickness in early age related macular degeneration (AMD) along 
the horizontal meridian. Retinal thickness for normal (black squares) and early AMD 
(open circles) participants from 2mm nasal (left) to 2mm temporal (right) of the fovea. 
A * indicates retinal locations where a difference between groups is significant at the 
P=0.05 level. Error bars indicate standard error at each point. Measurement 
locations identified as fovea (F), nasal (N) and temporal (T) with eccentricity of 0.5, 
1.0, 1.5 or 2.0 mm. 
 
FIGURE 3: Retinal thickness in early age related macular degeneration (AMD) along 
the vertical meridian. Retinal thickness for normal (black squares) and early AMD 
(open circles) participants from 2mm inferior (left) to 2mm superior (right) of the 
fovea. A * indicates retinal locations where a difference between groups is significant 
at the P=0.05 level. Error bars indicate standard error at each point. Measurement 
locations identified as fovea (F), superior (S) or inferior (I) with eccentricity of 0.5, 
1.0, 1.5 or 2.0 mm. 
 
FIGURE 4: Choroidal thickness in early age related macular degeneration (AMD) 
along the horizontal meridian. Choroidal thickness for normal (black squares) and 
early AMD (open circles) participants from 2mm nasal (left) to 2mm temporal (right) 
of the fovea. Error bars indicate standard error at each point. Measurement locations 
identified as fovea (F), nasal (N) and temporal (T) with eccentricity of 0.5, 1.0, 1.5 or 
2.0 mm. 
 
FIGURE 5: Choroidal thickness in early age related macular degeneration (AMD) 
along the vertical meridian. Choroidal thickness for normal (black squares) and early 
AMD (open circles) participants from 2mm inferior (left) to 2mm superior (right) of the 
fovea. Error bars indicate standard error at each point. Measurement locations 
identified as fovea (F), superior (S) or inferior (I) with eccentricity of 0.5, 1.0, 1.5 or 
2.0 mm. 
 
FIGURE 6: Retinal and optical coherence tomography (OCT) images for two study 
participants. Macular photographs and corresponding OCT sections (scan locations 
indicated by arrow) for participants 1 (Top) and 14 (Bottom). Participant 1: (Top Left) 
photograph of localised pigmentary disturbance, with few drusen present, (Top 
Right) OCT image of a drusen. Participant 14: (Bottom Left) photograph of multiple 
large soft drusen, pigmentary disturbances and drusenoid pigment epithelial 
detachments (PED), (Bottom Right) OCT image of a drusenoid PED and soft drusen. 
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TABLE 1. Clinical features of participants with early age-related macular degeneration 
Participant Presence of Clinical Feature
2
 
Contralateral 
Eye Status
4
 
Number Age (years) 
Tested 
Eye
1
 
Drusen 
>125µm 
(diameter) 
Drusen 
>10 
(number) 
Hyper/Hypo 
Pigmentation 
Drusenoid 
PED
3
 
1 56 R N N Y N Normal 
2 64 R Y N N N Normal 
3 80 L Y N Y N Normal 
4 79 L N N Y N Early 
5 70 L Y Y N N Early 
6 67 L Y N N N Early 
7 58 L Y N Y N Early 
8 87 L Y N N N Early 
9 73 L Y Y N N Early 
10 65 L N N Y N Wet 
11 74 L N N Y N Wet 
12 65 L Y Y Y N Wet 
13 75 R Y Y N N Wet 
14 78 R Y Y Y Y Wet 
15 79 R Y N N Y Wet 
16 75 L Y Y N Y Wet 
1
. Tested eye denoted by R (right eye) and L (left eye). 
2
. Presence of clinical features denoted by Y (yes) and N (no). 
3
. Pigment Epithelial Detachment (PED). 
4. “Early” or “Wet” denotes the subtype of age-related macular degeneration. 
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TABLE 2. Mean retinal thickness values at each location for both the control and 
early age-related macular degeneration groups 
 
 
Control Retinal Thickness 
(µm) 
Early AMD2 Retinal Thickness 
(µm) T-test3 
Location1 Mean ±SD Mean ±SD (* P<0.05) 
F 202 18 179 27 0.008* 
T0.5 274 24 247 31 0.011* 
T1.0 299 23 278 27 0.030* 
T1.5 282 22 267 20 0.038* 
T2.0 255 22 241 18 0.055 
N0.5 278 24 255 35 0.040* 
N1.0 313 19 292 30 0.028* 
N1.5 302 15 289 27 0.092 
N2.0 276 20 271 22 0.480 
S0.5 288 22 265 37 0.039* 
S1.0 306 23 288 25 0.045* 
S1.5 277 23 263 24 0.090 
S2.0 252 19 239 21 0.083 
I0.5 287 24 261 33 0.018* 
I1.0 306 15 292 22 0.036* 
I1.5 279 21 267 19 0.104 
I2.0 253 23 244 15 0.205 
1
. Measurement locations identified as fovea (F), nasal (N), temporal (T), superior (S) 
or inferior (I) with eccentricity of 0.5, 1.0, 1.5 or 2.0 mm. 
2
. Age-related macular degeneration (AMD) 
3
. Independent t-test; p-values for differences between groups at each location are 
denoted by a star (*) where a difference is significant at the P=0.05 level.  
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TABLE 3. Mean choroidal thickness values at each location for both the control and 
early age-related macular degeneration groups 
 
Control Choroid Thickness 
(µm) 
Early AMD2 Choroid 
Thickness (µm) T-test3 
Location1 Mean ±SD Mean ±SD (* P<0.05) 
F 213 63 231 70 0.429 
T0.5 219 60 220 72 0.974 
T1.0 213 65 211 71 0.940 
T1.5 203 62 203 54 0.982 
T2.0 195 54 204 47 0.593 
N0.5 219 71 229 71 0.710 
N1.0 199 74 218 80 0.505 
N1.5 188 77 200 85 0.678 
N2.0 162 70 162 80 1.000 
S0.5 207 62 207 65 0.973 
S1.0 210 75 208 79 0.952 
S1.5 209 76 203 86 0.830 
S2.0 195 63 207 83 0.640 
I0.5 218 62 240 74 0.360 
I1.0 215 64 230 69 0.529 
I1.5 206 72 218 65 0.624 
I2.0 196 54 212 73 0.487 
1
. Measurement locations identified as fovea (F), nasal (N), temporal (T), superior (S) 
or inferior (I) with eccentricity of 0.5, 1.0, 1.5 or 2.0 mm. 
2
. Age-related macular degeneration (AMD) 
3
. Independent t-test; p-values for differences between groups at each location did 
not exceed the P=0.05 significance level.  
 
 
 
